Navigation Links
MetaStat, Inc. Executes Two New Licenses
Date:4/27/2012

THE WOODLANDS, Texas, April 27, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST) announced today that it has executed two additional license agreements to patent applications and technology from the Albert Einstein College of Medicine of Yeshiva University. The first license agreement covers U.S. Patent Application No. 12/998,237 entitled "An In Vivo Quantitative Screening Test for Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey Edward Segall, John S. Condeelis, Dmitriy Kedrin, Jacco van Rheenan and Bojanna Gligorijevic. The second license includes two areas of intellectual property, U.S. Patent Application No. 11/659,514 entitled "Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells"; inventor John S. Condeelis (and its accompanying Canadian and European Patent Applications) and U.S. Provisional Patent Application (pending) entitled "Human Invasion Signature for Prognosis of Metastatic Risk"; inventors: John S. Condeelis and Antonia Patsialou.

We believe the technologies covered in these patent applications expand MetaStat's intellectual property in the field of highly metastatic cells.  Metastatic cells are the cancer cells that have developed the ability to transform themselves both physically and behaviorally from proiferative to metastatic. They migrate within the tumor, hone in on the tumor vasculature, form complexes on the surface of the blood vessels, and gain entry to the blood stream where they are carried to distant organs and tissues of the body to form metastases. These distant site metastases are the cause of the vast majority of fatalities from solid tumor cancers including approximately 90% of fatalities from breast cancer.

We believe the technology underlying "An In Vivo Quantitative Screening Test for Anti-Metastasis Treatment Efficacy" is expected to provide drug developers at MetaStat and potential corporate partners with drug development tools to develop the next generation of anti-metastatic drugs. There are currently no FDA approved drugs to target and kill these metastatic cells.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. We believe this is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were difficult because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

"Human Invasion Signature for Prognosis of Metastatic Risk," another result of our proprietary ability to isolate metastatic cells, describes the actual causative gene signature of metastatic cells. This approach contrasts with currently available technology that purports to evaluate risk of cancer recurrence by relying upon correlative mathematical algorithms developed through the statistical analysis of whole tumor tissue samples.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast is expected to be an important guide to treatment strategies for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying this diagnostic approach may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic.  Most significantly, we believe our platform technology provides us with targets of intervention in key pathways for the development of the first therapies that may preemptively reduce or eliminate metastasis thereby dramatically reducing fatalities.

Our technology platform and corresponding products result from over 15 years of collaboration involving four highly respected scientific institutions. We are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning cancer tumors. We have observed the behaviors and mechanisms used by metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site metastases.

For More Information, Contact:

Warren C. Lau
President & CEO
MetaStat, Inc.
(281) 363-0003


'/>"/>
SOURCE MetaStat, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc.
2. MetaStat, Inc. Completes Share Exchange with PhotoVoltaic Solar Cells, Inc.
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
9. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
10. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin Institute officially starts the ... special intensive summer training camp starts on June 17th on Shaolin Institute Atlanta ... children a fun and unique experience with an opportunity to learn KungFu martial ...
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... Whole Health ... jaw clipper that has been available via Amazon.com. This new style of nail ... nails. , The jaw opening is approximately 4mm and the actual handle is 2.5mm ...
(Date:5/29/2016)... ... ... "With 30 unique self-animating web themed intros and complete control over customization, ... Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume 3 ... Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a sleek ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
Breaking Medicine News(10 mins):